NCT05275959Completed
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
Implementation Research on the Construction and Scale Up Regarding To"Comorbidity-Co-causes-Joint-prevention" Comprehensive Demonstration District of Myopia and Obesity Among Children and Adolescents in Beijing Guided by RE-AIM Framework
Source: ClinicalTrials.gov · Last updated 31 Dec 2024
Brief summary (registry, in English)
Based on the RE-AIM framework, this project intends to integrate the prevention and control measures of myopia and obesity, and establish a set of key suitable technical packages and guarantee systems for the "comorbidity-common-cause-common prevention" of myopia and obesity in children and adolescents. Dong cheng ,Tongzhou and Changping District in total selected 18 intervention schools and 18 control schools to apply the application, integrate the resources of the "family-school-community-medical institution", and establish a comprehensive combination of myopia and obesity in children and adolescents In the prevention and control demonstration area, intervention study was conducted to evaluate the comprehensive intervention effect of myopia and obesity in children and adolescents in the demonstration area, and to promote it through the regional monitoring system in Beijing. This project is the first time to establish a district-level comprehensive prevention and control demonstration area for children and adolescents with myopia and obesity that can be promoted, including key appropriate technology packages and promotion and application strategies. Healthy Beijing 2030" plan laid the foundation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 3963 (actual)
- First submitted
- 20 Jan 2022
- Start date
- 8 Sept 2022
- Primary completion date
- 30 Apr 2024
- Lead sponsor
- Peking University
- Diseases
- Obesity
- NCT number
- NCT05275959
What you commit to
- Study type: Interventional
- Participants enrolled: 3963
- From 8 Sept 2022 to the primary completion date, 30 Apr 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have any weight loss behaviors such as inducing vomiting or taking weight loss drugs in past three months;
Other illness
- There are ophthalmic device diseases, such as keratitis, corneal ulcer, etc.;
- History of ophthalmic surgery, such as laser surgery;
- History of heart disease, hypertension, diabetes, tuberculosis, asthma, hepatitis, or nephritis;
- Obesity caused by endocrine diseases or side effects of drugs;
Other
- Visual problems such as color weakness and color blindness;
- Abnormal physical development, such as dwarfism or gigantism;
- Can not participate in school sports activities;
- Body deformities, such as severe scoliosis, chicken breasts, limps, pronounced O-or X-legs.
Who the study is looking for
- At 6-14 years old。
- The physical examination information at school is complete.
- There is no transfer plan within one year.
Age in the registry: 6 years to 14 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dongcheng Primary and Secondary School Health Care Center Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Health Education Center forPrimary and Secondary Schools Changping Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Tongzhou District Primary and Secondary School Health Care Institute Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
- Effectiveness of a School-Centered Intervention for Myopia and Obesity Comorbidity in Children: A Cluster-Randomized Trial.MedComm (2020) · 2026 · PMID 42928734
This page is information, not medical advice. Discuss any trial with your doctor.